Decision making
Can a clinicopathologic model predict cSCC metastasis risk?
Open access · cc by · source: Europe PMC
A Dutch-developed, England-validated model (C-index ~0.80–0.84) gives personalised absolute metastatic risk for cutaneous squamous cell carcinoma better than current staging for key decisions.
Key findings
Optimism-corrected C-index 0.80 in development and 0.84 in validation; calibration slope 0.96; improved decision-curve net benefit for follow-up/adjuvant thresholds. Released as an online calculator.
Methodology
Built nested case–control cohorts from nationwide Dutch (2007–2008) and English (2013–2015) cSCC data, developed a weighted Cox clinico-pathological model (8/11 variables) on n=390, validated on n=696, and compared discrimination/calibration/net benefit with BWH and AJCC staging.
Limitations
Still needs prospective decision-impact studies in other populations; nested case–control design estimates relative/absolute risk under sampling weights, not a simple consecutive series prevalence.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Not yet placed on a claim. This paper has study layers, but no concept page yet cites it as support, challenge, or qualifier.
Related papers in this topic
Same topic cluster — not a recommendation engine.